2530 Federal Register / Vol. 72, No.

12 / Friday, January 19, 2007 / Notices

and 7,500 ineligible screened persons MSM in year 1, IDU in year 2, and HET characteristics of the group.
during a 3-year period. Data collection in year 3. The type of data collected for Participation of respondents is
will rotate such that interviews will be each group will vary slightly due to voluntary and there is no cost to the
conducted among one group per year: different sampling methods and risk respondents other than their time.

ESTIMATED ANNUALIZED BURDEN HOURS

Average
Number of
Number of burden per Total burden
Respondents responses per
respondents response (in hours)
respondent (in hours)

MSM:
Screener only ........................................................................................... 5,000 1 5/60 417
Screener, survey, and testing .................................................................. 12,500 1 65/60 13,542
IDU:
Screener only ........................................................................................... 1,250 1 5/60 104
Screener, survey, and testing .................................................................. 12,500 1 90/60 18,750
HET:
Screener only ........................................................................................... 1,250 1 5/60 104
Screener, survey, and testing .................................................................. 12,500 1 75/60 15,625

Total ................................................................................................... ........................ ........................ ........................ 48,542

Dated: January 12, 2007. Matters to be Discussed: The agenda will http://www.phppo.cdc.gov/CLIAC/
Deborah Holtzman, include a review and discussion of the default.aspx.
National Breast and Cervical Cancer Early Times and Dates: 8:30 a.m.–5 p.m.,
Reports Clearance Officer, Centers for Disease
Detection Program components; and February 14, 2007; 8:30 a.m.–3 p.m.,
Control and Prevention.
discussion and review of related policies and February 15, 2007.
[FR Doc. E7–705 Filed 1–18–07; 8:45 am] emerging issues. Place: Omni Hotel at CNN Center, 100
BILLING CODE 4163–18–P Agenda items are subject to change as CNN Center, Atlanta, Georgia 30303; Phone:
priorities dictate. (404) 659–0000, Fax: (404) 525–5050 (http://
Contact Person for More Information: www.omnihotels.com/FindAHotel/
DEPARTMENT OF HEALTH AND Debra Younginer, Executive Secretary, AtlantaCNNCenter.aspx).
HUMAN SERVICES BCCEDCAC, Division of Cancer Prevention Status: Open to the public, limited only by
and Control, National Center for Chronic the space available. The meeting room
Centers for Disease Control and Disease Prevention and Health Promotion, accommodates approximately 100 people.
CDC, 4770 Buford Highway, Mailstop K–57, Purpose: This committee is charged with
Prevention Chamblee, Georgia 30316, Telephone: 770– providing scientific and technical advice and
488–1074. guidance to the Secretary of Health and
Breast and Cervical Cancer Early The Director, Management Analysis and
Detection and Control Advisory Human Services, the Assistant Secretary for
Services Office, has been delegated the Health, and the Director, CDC, regarding the
Committee authority to sign Federal Register notices need for, and the nature of, revisions to the
pertaining to announcements of meetings and standards under which clinical laboratories
In accordance with section 10(a)(2)of other committee management activities for are regulated, the impact on medical and
the Federal Advisory Committee Act both CDC and NCEH/ATSDR. laboratory practice of proposed revisions to
(Pub. L. 92–463), the Centers for Disease Dated: January 12, 2007. the standards, and the modification of the
Control and Prevention (CDC) Edward Schultz, standards to accommodate technological
announces the aforementioned Acting Director, Management Analysis and
advances.
committee meeting: Matters to be Discussed: The agenda will
Services Office, Center for Disease Control
include updates from the CDC, the Centers
Times and Dates: 8:30 a.m.–5 p.m., and Prevention.
for Medicare & Medicaid Services, and the
February 6, 2007; 8:30 a.m.–3 p.m., February [FR Doc. E7–721 Filed 1–18–07; 8:45 am] Food and Drug Administration; discussion of
7, 2007. BILLING CODE 4163–18–P the status of the ‘‘Notice of Proposed
Place: Centers for Disease Control and Rulemaking’’ for genetic testing;
Prevention, 1600 Clifton Road, NE., Tom presentations and discussion concerning the
Harkin Global Community Center, Building DEPARTMENT OF HEALTH AND future of health laboratory practice
19, Atlanta, Georgia 30333, Telephone: 404– HUMAN SERVICES specifically focusing on simple testing in
639–1717. diverse sites; reports and discussions
Status: Open to the public, limited only by Centers for Disease Control and addressing the impact of the Morbidity and
the space available. Prevention Mortality Weekly Report (MMWR)
Purpose: The committee is charged with Publication of ‘‘Good Laboratory Practices for
advising the Secretary, Department of Health Clinical Laboratory Improvement Waived Testing Sites’’; a report from the
and Human Services, and the Director, CDC, CLIAC Workgroup on ‘‘The Impact of Rapid
Advisory Committee
regarding the early detection and control of and Molecular Tests for Infectious Disease
breast and cervical cancer. The committee In accordance with section 10(a)(2) of Agents on Public Health’’ and discussion of
makes recommendations regarding national the Federal Advisory Committee Act the workgroup’s proposals related to such;
program goals and objectives; (Pub. L. 92–463), the Centers for Disease and presentations and discussion concerning
sroberts on PROD1PC70 with NOTICES

implementation strategies; and program Control and Prevention (CDC) rapid HIV testing. Agenda items are subject
priorities including surveillance, to change as priorities dictate.
announces the following committee
epidemiologic investigations, education and Providing Oral or Written Comments: It is
training, information dissemination, meeting. the policy of CLIAC to accept written public
professional interactions and collaborations, Name: Clinical Laboratory Improvement comments and provide a brief period for oral
and policy. Advisory Committee (CLIAC). Web site: public comments whenever possible.

VerDate Aug<31>2005 18:10 Jan 18, 2007 Jkt 211001 PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 E:\FR\FM\19JAN1.SGM 19JAN1